Skip to main content

Diabetes stocks are surprise winners from Novo Nordisk’s Wegovy study, analysts say

Eli Lilly also scores, analysts say, as trial results leave door open for Zepbound to top Wegovy’s benefits.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.